Media release
For immediate release
January 10 2014
Bee Venom and Chilli Extract Combine In New Joint Treatment
A new 100% natural product combining New Zealand bee venom and capsaicin (chilli pepper extract) designed to give rapid
relief to joints – Rubeeven – was launched today. The product is available now atwww.rubeeven.com.
Worldwide, around one in three people suffer from joint stiffness or discomfort as a result of conditions such as
arthritis. HoneyLab, the developers of the product, say the unique patent-pending blend of two powerful natural products
targets joint stiffness safely and rapidly.
“For centuries, people have used bee venom for arthritis, and capsaicin is a proven treatment,” says international
complementary medicines expert and Rubeeven creator Professor Shaun Holt.
“This is a completely new approach to joint relief, using the power of two natural products.”
The dual-action cream works in two ways. Capsaicin warms the treated area, increasing blood flow, relieving pain and
helping the bee venom penetrate the joints.
“Studies have shown that bee venom causes local release of the body’s own anti-inflammatory steroids, which is why bee
venom has been described as ’nature’s cortisol shot’,” says Professor Holt.
“We’re confident Rubeeven will make a difference to the lives of thousands of New Zealanders suffering from joint
stiffness and discomfort.”
The Wellington-based company behind onesay Rubeeven – HoneyLab Ltd – is dedicated to research and innovation of natural
products.
Founded by Professor Holt and businessman Laurence Greig in 2009, HoneyLab is at the forefront of international honey
research with its mission to unlock the potential of natural products including kanuka honey and bee venom. To date, the
company has launched HoneyLab pharmaceutical kanuka honey to treat various skin diseases and Kanu Bee Venom, a high
strength clinically proven anti-ageing beauty treatment.
Professor Holt is a world-leading medical researcher, who has developed medicines for some of the world’s largest
pharmaceutical companies.
ENDS